<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xoma Corp — News on 6ix</title>
<link>https://6ix.com/company/xoma-corp</link>
<description>Latest news and press releases for Xoma Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Mar 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xoma-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dcf478dffbe2df12482e.webp</url>
<title>Xoma Corp</title>
<link>https://6ix.com/company/xoma-corp</link>
</image>
<item>
<title>XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements</guid>
<pubDate>Wed, 18 Mar 2026 10:00:00 GMT</pubDate>
<description>Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full year 2024 Business development: Added 22 assets to portfolio, including five programs in Phase 2 or Phase 3 development Stock buyback program: Repurchased and retired 648,048 shares for an aggregate of $16.0 million Company acquisitions: Completed seven acquisitions, accumulating $11.</description>
</item>
<item>
<title>XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026</guid>
<pubDate>Thu, 12 Mar 2026 10:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update. The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events).</description>
</item>
<item>
<title>XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-145300616</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-145300616</guid>
<pubDate>Mon, 09 Feb 2026 14:53:00 GMT</pubDate>
<description>Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company successfully completed its previously announced tender offer to acquire all outstanding shares of Generation Bio C</description>
</item>
<item>
<title>XOMA Royalty Announces CFO Transition</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-cfo-transition-123000616</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-cfo-transition-123000616</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. “Tom’s leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator,” stated Owen Hughes, XOMA Royalty’s Chief Executive Officer. “On behalf of the</description>
</item>
<item>
<title>XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-takeda-execute-strategic-123000535</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-takeda-execute-strategic-123000535</guid>
<pubDate>Tue, 30 Dec 2025 12:30:00 GMT</pubDate>
<description>– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda th</description>
</item>
<item>
<title>XOMA Royalty Declares Quarterly Preferred Stock Dividends</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-declares-quarterly-preferred-123000269</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-declares-quarterly-preferred-123000269</guid>
<pubDate>Mon, 22 Dec 2025 12:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of</description>
</item>
<item>
<title>XOMA Royalty Enters into Agreement to Acquire Generation Bio</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-enters-agreement-acquire-220000213</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-enters-agreement-acquire-220000213</guid>
<pubDate>Mon, 15 Dec 2025 22:00:00 GMT</pubDate>
<description>- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced</description>
</item>
<item>
<title>XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-transaction-140000618</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-transaction-140000618</guid>
<pubDate>Fri, 05 Dec 2025 14:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shar</description>
</item>
<item>
<title>Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty</title>
<link>https://6ix.com/company/xoma-corp/news/mural-oncology-announces-final-cash-consideration-payable-on-closing-of-acquisition-by-xoma-royalty</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/mural-oncology-announces-final-cash-consideration-payable-on-closing-of-acquisition-by-xoma-royalty</guid>
<pubDate>Wed, 26 Nov 2025 14:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreem</description>
</item>
<item>
<title>XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-transactions-124500704</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-transactions-124500704</guid>
<pubDate>Fri, 21 Nov 2025 12:45:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) with a nominal value of €0.12 per share (“Shares”). LAVA shareholders received $1.04 in cash per Share and a non-transferrable contingent value right (“CVR”) per Share representing the right to receive certain cash paym</description>
</item>
<item>
<title>XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-third-quarter-123000651</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-third-quarter-123000651</guid>
<pubDate>Wed, 12 Nov 2025 12:30:00 GMT</pubDate>
<description>Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty’s acquisitions of Turnstone Biologics and HilleVax; • announced acquisitions of LAVA Therapeutics and Mural Oncology; • acted as structuring agent for XenoTherapeutics’ acquisition of ESSA Pharma. Key Pipeline advancements: • Zevra Therapeutics submitted a Marketing Authorization Appl</description>
</item>
<item>
<title>LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline</title>
<link>https://6ix.com/company/xoma-corp/news/lava-therapeutics-nv-shareholders-are-reminded-to-tender-shares-for-xoma-royalty-transaction-before-november-12-2025-deadline</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/lava-therapeutics-nv-shareholders-are-reminded-to-tender-shares-for-xoma-royalty-transaction-before-november-12-2025-deadline</guid>
<pubDate>Mon, 10 Nov 2025 21:09:00 GMT</pubDate>
<description>UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation (“XOMA”) (NASDAQ: XOMA). On August 4, 2025, XOMA and LAVA announced they had entered into a share purchase agreement. More recently, on October 17, 2025, XOMA announced it had extended its offer (the “Offer”) to purchase all outstanding common shares of LAVA unt</description>
</item>
<item>
<title>Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty</title>
<link>https://6ix.com/company/xoma-corp/news/mural-oncology-announces-that-mural-shareholders-approve-the-proposed-acquisition-by-xra-5-corp-a-wholly-owned-subsidiary-of-xoma-royalty</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/mural-oncology-announces-that-mural-shareholders-approve-the-proposed-acquisition-by-xra-5-corp-a-wholly-owned-subsidiary-of-xoma-royalty</guid>
<pubDate>Fri, 24 Oct 2025 20:25:00 GMT</pubDate>
<description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. (“Sub”), a wholly owned subsidiary of XOMA Royalty Cor</description>
</item>
<item>
<title>XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-lava-therapeutics-announce-154500116-1</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-lava-therapeutics-announce-154500116-1</guid>
<pubDate>Fri, 17 Oct 2025 15:45:00 GMT</pubDate>
<description>- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that they have reached an agreement to amend their previously announced definitive share purchase agreement (th</description>
</item>
<item>
<title>XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-extends-tender-offer-204300729</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-extends-tender-offer-204300729</guid>
<pubDate>Thu, 02 Oct 2025 20:43:00 GMT</pubDate>
<description>EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right (“CVR”) per share representin</description>
</item>
<item>
<title>XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-130000843</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-130000843</guid>
<pubDate>Wed, 17 Sep 2025 13:00:00 GMT</pubDate>
<description>HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NAS</description>
</item>
<item>
<title>XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-present-h-c-113000240</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-present-h-c-113000240</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference. Mr. Hughes and Mr. Sitko will present on Monday, September 8, 2025 at 9:00 AM ET. The webcast for the presentation can be accessed by visiting https://bit.ly/4mjFgkY. XOMA Royal</description>
</item>
<item>
<title>Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share</title>
<link>https://6ix.com/company/xoma-corp/news/mural-oncology-announces-entry-into-agreement-to-be-acquired-by-xra-5-corp-a-wholly-owned-subsidiary-of-xoma-royalty-for-between-dollar2035-and-dollar224-in-cash-per-share</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/mural-oncology-announces-entry-into-agreement-to-be-acquired-by-xra-5-corp-a-wholly-owned-subsidiary-of-xoma-royalty-for-between-dollar2035-and-dollar224-in-cash-per-share</guid>
<pubDate>Wed, 20 Aug 2025 12:49:00 GMT</pubDate>
<description>WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued and to be issued share capital of Mur</description>
</item>
<item>
<title>XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-second-quarter-113000151</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-reports-second-quarter-113000151</guid>
<pubDate>Wed, 13 Aug 2025 11:30:00 GMT</pubDate>
<description>Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics. Company acquisitions: Announced XOMA Royalty’s acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax; acted as structuring agent and provided financing for XenoTherapeutics’ acquisition of ESSA Pharma; completed the sale of K</description>
</item>
<item>
<title>XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics</title>
<link>https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-130000478</link>
<guid isPermaLink="true">https://6ix.com/company/xoma-corp/news/xoma-royalty-announces-closing-tender-130000478</guid>
<pubDate>Mon, 11 Aug 2025 13:00:00 GMT</pubDate>
<description>- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biolog</description>
</item>
</channel>
</rss>